RESPONSE TO LETTER

Response to Article "Microfluidic Synthesis of miR-200c-3p Lipid Nanoparticles: Targeting ZEB2 to Alleviate Chondrocyte Damage in Osteoarthritis" [Response to Letter]

Dong Zheng¹, Tong Chen ¹/₀², Kaiyuan Yang¹, Guangrong Yin¹, Yang Chen³, Jianchao Gui⁴, Chao Xu¹, Songwei Lv⁵

¹Department of Orthopedics, The Affiliated Changzhou No.2 People's Hospital with Nanjing Medical University, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, People's Republic of China; ²Department of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China; ³Changzhou Productivity Development Center, Changzhou, People's Republic of China; ⁴Department of Sports Medicine and Joint Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, People's Republic of China; ⁵School of Pharmacy, Changzhou University, Changzhou, People's Republic of China

Correspondence: Chao Xu, Email xuchao_06@163.com; Songwei Lv, Email lvsw@cczu.edu.cn

Dear editor

Thank you for your letter and for the readers' comments concerning our manuscript entitled "Microfluidic Synthesis of miR-200c-3p Lipid Nanoparticles: Targeting ZEB2 to Alleviate Chondrocyte Damage in Osteoarthritis". These opinions have a certain guiding significance for our follow-up research.

Thank you for your interest in our research and your question regarding the lack of animal experiments in our studies. We want to clarify that we are conducting relevant animal experiments; however, due to the need for ethical approval and the duration of the experimental cycle, we do not yet have complete results. We look forward to sharing our findings with you as soon as they are available. The stability and potential side effects of nanomaterials pose significant challenges to the advancement of nanopharmaceutics. To address this issue, we have chosen liposome nanomaterials, which are widely used in clinical practice, to facilitate the process of clinical transformation. The pathological mechanisms of osteoarthritis are quite complex. This paper primarily focuses on the inflammatory response triggered by lipopolysaccharides (LPS). In future work, we will further explore related mechanisms, including cartilage degeneration, oxidative stress, and synovial disease.

Disclosure

The authors report no conflict of interest in this communication.

Dove Medical Press encourages responsible, free and frank academic debate. The contentTxt of the International Journal of Nanomedicine 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the International Journal of Nanomedicine editors. While all reasonable steps have been taken to confirm the contentTxt of each letter, Dove Medical Press accepts no liability in respect of the contentTxt of any letter, nor is it responsible for the contentTxt and accuracy of any letter to the editor.

International Journal of Nanomedicine



Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch[®], Current Contents[®]/Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http:// www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/international-journal-of-nanomedicine-journal

https://doi.org/10.2147/IJN.S520821

Received: 5 February 2025 Accepted: 6 February 2025 Published: 13 February 2025

International Journal of Nanomedicine 2025:20 1949

1949

© 2025 Zheng et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).